RARE DISEASE
Spinocerebellar ataxia type 6
Spinocerebellar ataxia type 6
Spinocerebellar ataxia type 6
Synonyms: SCA6
Synonyms: SCA6
Synonyms: SCA6
Drug discovery
0
drugs
With orphan designations
Overview
Spinocerebellar ataxia type 6 (SCA6) is an autosomal dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansions (20-33 repeats) in the CACNA1A gene encoding voltage-gated calcium channels. Characterized by late-onset progressive cerebellar dysfunction (40s-50s), it presents with gait ataxia, dysarthria, nystagmus, and impaired coordination. Distinct from other SCAs, it typically progresses slowly without shortened lifespan, though some patients develop episodic symptoms overlapping with EA2. Neuropathology involves Purkinje cell degeneration and intracellular calcium channel aggregates [1][2][6][11].
Burden
Progressive disability: 53% require walking aids by mean age 53, wheelchair dependence by 60 [4][11]
High quality-of-life impact from dysphagia (aspiration risk), depression (50%), and caregiver dependence [4][7][11]
Annual neurologic decline (~0.8 SARA points) necessitates long-term multidisciplinary care [4][11]
Therapies
Symptomatic management: Acetazolamide for episodic ataxia, physical/occupational therapy for mobility, speech therapy for dysarthria [6][11]
Experimental approaches: RNA interference (RNAi), antisense oligonucleotides (ASOs), and riluzole under investigation [3][8][13]
No disease-modifying therapies; clinical trials focus on ion channel modulation [8][13]
Categories: rare genetic diseases, rare neurological diseases
Research Papers
288 drug discovery papers about Spinocerebellar ataxia type 6, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
288 drug discovery papers about Spinocerebellar ataxia type 6, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-11 | Safety and preliminary efficacy of autologous bone marrow-derived mesenchymal stem cell transplantation in hereditary cerebellar ataxia: phase I/IIa clinical trial.
Hereditary cerebellar ataxias (HCA) encompass a spectrum of pathological conditions affecting the cerebellum. Currently, there is growing interest in the potential role of mesenchymal stem cells (MSCs) as an investigational therapeutic approach for this condition. Hence, the objective of this single-center, open-label, phase I/IIa clinical trial was to assess the safety and exploratory clinical and biomarker changes following a single intrathecal injection of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in HCA. Ten confirmed patients with HCA entered the study and underwent a single dose of (1 × 106 cells/kg BW) intrathecal transplantation of BM-MSCs at passage 3. During the follow-up, patients were evaluated four times (one month before the intervention (-1), months 1, 3, and 6). Assessments included safety evaluation, Scale for the Assessment and Rating of Ataxia (SARA), GAD 65-antibody, and specific cytokines in the patient's serum and cerebrospinal fluid (CSF) samples. No severe adverse effects were observed following the cell transplantation procedure. A decreasing trend in SARA score was observed, with a statistically significant difference at month 6 compared with baseline. Except for one patient, GAD-65 antibody levels remained within the normal range in all patients. In one patient with markedly elevated baseline GAD-65 titers, serum and CSF GAD-65 levels decreased from 814 IU/mL and 781 IU/mL, respectively, to values within the normal range after 3 months. Significant changes were observed in selected inflammatory biomarkers, including decreased serum IL-6 at month 3, decreased CSF TNF-alpha at months 1 and 3, and increased serum IL-10 during follow-up. CSF IL-6 did not show a significant decrease. The findings support the short-term safety and tolerability of a single intrathecal dose of autologous BM-MSCs in this small HCA cohort. The study provides preliminary signals of possible clinical and biomarker changes; however, efficacy cannot be established due to the uncontrolled design, small sample size, disease heterogeneity, and short follow-up. Larger randomized controlled trials are required to validate these exploratory findings. This clinical trial was registered with the Iranian Registry of Clinical Trials (ID: IRCT20160809029275N3).
2026-07-10 | Immune Activation and Glial Dysfunction in Spinocerebellar Ataxias: From Cerebellar Landscape to Disease-Driven Mechanisms and Immunomodulation.
Spinocerebellar ataxias (SCAs) comprise a clinically and genetically heterogeneous group of autosomal dominant neurodegenerative disorders. Despite the recognized role of specialized cerebellar glia in cerebellar development and dysfunction, immune activation and non-immune glial responses remain understudied in SCAs. This narrative review compiles evidence from cellular, animal, and human models on the cerebellar immune landscape and the specific pathways that drive homeostatic failure and neuroinflammatory cascades across SCA subtypes. Microgliosis emerges consistently-and often early- as a generalized feature across the SCA spectrum, preceding neurodegeneration in several subtypes. Concurrently, reactive astrogliosis extends broadly, reflecting widespread macroglial surveillance and metabolic stress regulation throughout histologically preserved gray matter, with specialized homeostatic failure of Bergmann glia in SCA1, SCA2, and SCA7. Peripheral inflammation, manifests as early as the prodromal stage and correlates with the cognitive-affective deficits in SCA2 and associates with the mutation size in SCA3, positioning it as integral to pathogenesis rather than epiphenomenal. Diverse, partially shared signaling pathways converge on multi-lineage glial breakdown and reciprocal neuroimmune crosstalk. These mechanisms involve NF-κB (SCA1,3,17), cGAS-STING (SCA2), TLR/MyD88 (SCA6), and JNK/c-Jun (SCA1,2,7). This review establishes abnormal reciprocal immune/non-immune glia crosstalk as a core pathogenic principle across SCAs, revealing novel therapeutic opportunities. In fact, targeting convergent signaling nodes such as NF-κB, or JNK pathways, holds disease-modifying potential across multiple subtypes. Future research should prioritize standardized comparative studies, longitudinal analyses linking both inflammation and non-immune glial pathology to clinical progression, and clinical trials evaluating targeted immunomodulatory and glial homeostatic-supportive agents.
2026-07-09 | Gene therapy for spinocerebellar ataxias.
Spinocerebellar ataxias (SCAs), rare neurodegenerative disorders characterized by progressive cerebellar degeneration, cause impaired balance and motor dysfunction. Although most cases are inherited, sporadic forms also occur, and effective disease-modifying therapies remain unavailable despite advances in understanding their genetic and molecular mechanisms. This unmet need is particularly significant because many SCAs are monogenic disorders caused by well-characterized mutations, making them promising candidates for gene- and RNA-based therapies. Recent advances in antisense oligonucleotides, RNA interference, vector engineering, and genome editing have increasingly enabled the alignment of therapeutic strategies with specific mutational architectures. Therefore, this review aims to examine how genetic subclassification informs platform selection, summarize recent advances in gene- and RNA-based therapeutics, and outline key translational barriers to clinical implementation in SCAs.
2026-05-28 | Aromatic-Turmerone Analogs Activate Chaperone-Mediated Autophagy and Ameliorate Dendritic Shrinkage in Purkinje Cell Models of Spinocerebellar Ataxia.
We recently demonstrated that aromatic (ar)-turmerone analogs ((E)-5-methyl-1-(p-tolyl)hexa-1,4-dien-3-one [A2] and (E)-1-(4-methoxyphenyl)-5-methylhexa-1,4-dien-3-one [A4]) activate chaperone-mediated autophagy (CMA), a pathway in the autophagy-lysosome protein degradation system, in SH-SY5Y cells. Our previous studies revealed that the impairment of CMA and microautophagy (mA), another autophagy-related pathway, and dendritic shrinkage were observed in primary cultured Purkinje cells (PCs) expressing causal proteins of spinocerebellar ataxia (SCA), an autosomal dominant neurodegenerative disease. In the present study, we first investigated the effects of A2 and A4 on lysosomal protein degradation and dendritic morphology in cerebellar primary cultured PCs. Both compounds enhanced dendritic development and activated CMA in cultured PCs. These effects were significantly suppressed by the inhibitors of nuclear factor erythroid 2-related factor 2 and p38. We next examined the effects of A2 and A4 on PCs expressing several types of SCA-causing proteins (SCA model PCs). Both chemicals ameliorated the dendritic shrinkage and restored the decreased CMA/mA activity in several SCA model PCs. These findings suggest that the ar-turmerone analogs A2 and A4 improve the in vitro phenotype of SCA model PCs through CMA activation, highlighting the therapeutic potential of these analogs for various types of SCAs.
2026-05-10 | Ion Channel Degeneracy Masks Channelopathy in SCA6: Calcium Homeostasis Collapse as a Proteotoxic Stress Mechanism
Spinocerebellar ataxia type 6 (SCA6) is caused by polyglutamine expansion in CACNA1A, encoding the P/Q-type calcium channel (CaPQ). The prevailing channelopathy hypothesis posits that CaPQ loss directly disrupts Purkinje cell firing. Here we test this hypothesis computationally using the Universal Cell v5 biophysically constrained Hodgkin-Huxley framework, simulating 236 elite Purkinje neurons derived from 1.5 million Monte Carlo samples and constrained by Kozareva et al. (2021) cerebellar scRNA-seq data (n = 16,634 cells). Progressive CaPQ reduction — including complete knockout — produced no statistically significant change in firing frequency (51.0 → 51.4 Hz, p ≈ 1.0), demonstrating strong ion channel degeneracy. A sharp phase transition emerged only when CaT was additionally ablated, producing two mechanistically distinct death modes: ca_er_overload and drive_loss. A mechanistic negative control (Ctrl_noCaPQ) confirmed that CaL and CaT loss triggers terminal collapse even with CaPQ fully intact (83.9% survival vs. 83.9% in full disease, p = 1.000), causally excluding CaPQ loss as the primary driver. Rescue simulations across eight mechanisms revealed that HCN augmentation provided the most robust rescue (up to 64%), while PMCA augmentation rescued 12.8–17.1% of drive_loss cells in early phases but collapsed after the Phase 2→3 transition (Fisher's exact OR = ∞, p < 0.0001), defining a therapeutic window closure. Kv3 augmentation was ineffective across all conditions and death modes (0%), ruling out electrical repolarization failure. Independent validation against the Huang et al. (2026) SCA6 mouse time series (GSE264100; n = 40, ages 3–19 months) confirmed the predicted molecular fingerprint: Cacna1h showed progressive divergence from wild-type (WT↑ vs SCA6↓; Spearman ρ = −1.0, p < 0.001), Scn8a declined at 19 months (Log2FC = −0.53, p = 0.016), and PMCA2/Atp2b2 collapsed at late stage, consistent with the computed therapeutic window closure. ER stress markers (BiP/Hspa5 spike-then-collapse; CHOP/Ddit3 ↑ → p_adj = 4.6 × 10⁻¹²) confirmed proteotoxic rather than electrophysiological pathology. We conclude that SCA6 is not a primary channelopathy: ion channel degeneracy masks CaPQ loss at the firing level, while downstream CaT erosion and ER calcium overload drive neurodegeneration independently of P/Q-type channel function.
2026-07-11 | Safety and preliminary efficacy of autologous bone marrow-derived mesenchymal stem cell transplantation in hereditary cerebellar ataxia: phase I/IIa clinical trial.
Hereditary cerebellar ataxias (HCA) encompass a spectrum of pathological conditions affecting the cerebellum. Currently, there is growing interest in the potential role of mesenchymal stem cells (MSCs) as an investigational therapeutic approach for this condition. Hence, the objective of this single-center, open-label, phase I/IIa clinical trial was to assess the safety and exploratory clinical and biomarker changes following a single intrathecal injection of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in HCA. Ten confirmed patients with HCA entered the study and underwent a single dose of (1 × 106 cells/kg BW) intrathecal transplantation of BM-MSCs at passage 3. During the follow-up, patients were evaluated four times (one month before the intervention (-1), months 1, 3, and 6). Assessments included safety evaluation, Scale for the Assessment and Rating of Ataxia (SARA), GAD 65-antibody, and specific cytokines in the patient's serum and cerebrospinal fluid (CSF) samples. No severe adverse effects were observed following the cell transplantation procedure. A decreasing trend in SARA score was observed, with a statistically significant difference at month 6 compared with baseline. Except for one patient, GAD-65 antibody levels remained within the normal range in all patients. In one patient with markedly elevated baseline GAD-65 titers, serum and CSF GAD-65 levels decreased from 814 IU/mL and 781 IU/mL, respectively, to values within the normal range after 3 months. Significant changes were observed in selected inflammatory biomarkers, including decreased serum IL-6 at month 3, decreased CSF TNF-alpha at months 1 and 3, and increased serum IL-10 during follow-up. CSF IL-6 did not show a significant decrease. The findings support the short-term safety and tolerability of a single intrathecal dose of autologous BM-MSCs in this small HCA cohort. The study provides preliminary signals of possible clinical and biomarker changes; however, efficacy cannot be established due to the uncontrolled design, small sample size, disease heterogeneity, and short follow-up. Larger randomized controlled trials are required to validate these exploratory findings. This clinical trial was registered with the Iranian Registry of Clinical Trials (ID: IRCT20160809029275N3).
2026-07-10 | Immune Activation and Glial Dysfunction in Spinocerebellar Ataxias: From Cerebellar Landscape to Disease-Driven Mechanisms and Immunomodulation.
Spinocerebellar ataxias (SCAs) comprise a clinically and genetically heterogeneous group of autosomal dominant neurodegenerative disorders. Despite the recognized role of specialized cerebellar glia in cerebellar development and dysfunction, immune activation and non-immune glial responses remain understudied in SCAs. This narrative review compiles evidence from cellular, animal, and human models on the cerebellar immune landscape and the specific pathways that drive homeostatic failure and neuroinflammatory cascades across SCA subtypes. Microgliosis emerges consistently-and often early- as a generalized feature across the SCA spectrum, preceding neurodegeneration in several subtypes. Concurrently, reactive astrogliosis extends broadly, reflecting widespread macroglial surveillance and metabolic stress regulation throughout histologically preserved gray matter, with specialized homeostatic failure of Bergmann glia in SCA1, SCA2, and SCA7. Peripheral inflammation, manifests as early as the prodromal stage and correlates with the cognitive-affective deficits in SCA2 and associates with the mutation size in SCA3, positioning it as integral to pathogenesis rather than epiphenomenal. Diverse, partially shared signaling pathways converge on multi-lineage glial breakdown and reciprocal neuroimmune crosstalk. These mechanisms involve NF-κB (SCA1,3,17), cGAS-STING (SCA2), TLR/MyD88 (SCA6), and JNK/c-Jun (SCA1,2,7). This review establishes abnormal reciprocal immune/non-immune glia crosstalk as a core pathogenic principle across SCAs, revealing novel therapeutic opportunities. In fact, targeting convergent signaling nodes such as NF-κB, or JNK pathways, holds disease-modifying potential across multiple subtypes. Future research should prioritize standardized comparative studies, longitudinal analyses linking both inflammation and non-immune glial pathology to clinical progression, and clinical trials evaluating targeted immunomodulatory and glial homeostatic-supportive agents.
2026-07-09 | Gene therapy for spinocerebellar ataxias.
Spinocerebellar ataxias (SCAs), rare neurodegenerative disorders characterized by progressive cerebellar degeneration, cause impaired balance and motor dysfunction. Although most cases are inherited, sporadic forms also occur, and effective disease-modifying therapies remain unavailable despite advances in understanding their genetic and molecular mechanisms. This unmet need is particularly significant because many SCAs are monogenic disorders caused by well-characterized mutations, making them promising candidates for gene- and RNA-based therapies. Recent advances in antisense oligonucleotides, RNA interference, vector engineering, and genome editing have increasingly enabled the alignment of therapeutic strategies with specific mutational architectures. Therefore, this review aims to examine how genetic subclassification informs platform selection, summarize recent advances in gene- and RNA-based therapeutics, and outline key translational barriers to clinical implementation in SCAs.
2026-05-28 | Aromatic-Turmerone Analogs Activate Chaperone-Mediated Autophagy and Ameliorate Dendritic Shrinkage in Purkinje Cell Models of Spinocerebellar Ataxia.
We recently demonstrated that aromatic (ar)-turmerone analogs ((E)-5-methyl-1-(p-tolyl)hexa-1,4-dien-3-one [A2] and (E)-1-(4-methoxyphenyl)-5-methylhexa-1,4-dien-3-one [A4]) activate chaperone-mediated autophagy (CMA), a pathway in the autophagy-lysosome protein degradation system, in SH-SY5Y cells. Our previous studies revealed that the impairment of CMA and microautophagy (mA), another autophagy-related pathway, and dendritic shrinkage were observed in primary cultured Purkinje cells (PCs) expressing causal proteins of spinocerebellar ataxia (SCA), an autosomal dominant neurodegenerative disease. In the present study, we first investigated the effects of A2 and A4 on lysosomal protein degradation and dendritic morphology in cerebellar primary cultured PCs. Both compounds enhanced dendritic development and activated CMA in cultured PCs. These effects were significantly suppressed by the inhibitors of nuclear factor erythroid 2-related factor 2 and p38. We next examined the effects of A2 and A4 on PCs expressing several types of SCA-causing proteins (SCA model PCs). Both chemicals ameliorated the dendritic shrinkage and restored the decreased CMA/mA activity in several SCA model PCs. These findings suggest that the ar-turmerone analogs A2 and A4 improve the in vitro phenotype of SCA model PCs through CMA activation, highlighting the therapeutic potential of these analogs for various types of SCAs.
2026-05-10 | Ion Channel Degeneracy Masks Channelopathy in SCA6: Calcium Homeostasis Collapse as a Proteotoxic Stress Mechanism
Spinocerebellar ataxia type 6 (SCA6) is caused by polyglutamine expansion in CACNA1A, encoding the P/Q-type calcium channel (CaPQ). The prevailing channelopathy hypothesis posits that CaPQ loss directly disrupts Purkinje cell firing. Here we test this hypothesis computationally using the Universal Cell v5 biophysically constrained Hodgkin-Huxley framework, simulating 236 elite Purkinje neurons derived from 1.5 million Monte Carlo samples and constrained by Kozareva et al. (2021) cerebellar scRNA-seq data (n = 16,634 cells). Progressive CaPQ reduction — including complete knockout — produced no statistically significant change in firing frequency (51.0 → 51.4 Hz, p ≈ 1.0), demonstrating strong ion channel degeneracy. A sharp phase transition emerged only when CaT was additionally ablated, producing two mechanistically distinct death modes: ca_er_overload and drive_loss. A mechanistic negative control (Ctrl_noCaPQ) confirmed that CaL and CaT loss triggers terminal collapse even with CaPQ fully intact (83.9% survival vs. 83.9% in full disease, p = 1.000), causally excluding CaPQ loss as the primary driver. Rescue simulations across eight mechanisms revealed that HCN augmentation provided the most robust rescue (up to 64%), while PMCA augmentation rescued 12.8–17.1% of drive_loss cells in early phases but collapsed after the Phase 2→3 transition (Fisher's exact OR = ∞, p < 0.0001), defining a therapeutic window closure. Kv3 augmentation was ineffective across all conditions and death modes (0%), ruling out electrical repolarization failure. Independent validation against the Huang et al. (2026) SCA6 mouse time series (GSE264100; n = 40, ages 3–19 months) confirmed the predicted molecular fingerprint: Cacna1h showed progressive divergence from wild-type (WT↑ vs SCA6↓; Spearman ρ = −1.0, p < 0.001), Scn8a declined at 19 months (Log2FC = −0.53, p = 0.016), and PMCA2/Atp2b2 collapsed at late stage, consistent with the computed therapeutic window closure. ER stress markers (BiP/Hspa5 spike-then-collapse; CHOP/Ddit3 ↑ → p_adj = 4.6 × 10⁻¹²) confirmed proteotoxic rather than electrophysiological pathology. We conclude that SCA6 is not a primary channelopathy: ion channel degeneracy masks CaPQ loss at the firing level, while downstream CaT erosion and ER calcium overload drive neurodegeneration independently of P/Q-type channel function.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.